Sotrovimab
- Generic Name
- Sotrovimab
- Brand Names
- Xevudy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2423014-07-5
- Unique Ingredient Identifier
- 1MTK0BPN8V
- Background
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of death or hospitalizatio...
- Indication
In Europe, sotrovimab is indicated for the treatment of COVID-19 in patients ≥12 years old and weighing ≥40kg who do not require supplemental oxygen and are at high risk of progressing to severe disease.
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19)
- Associated Therapies
- -
Randomised Evaluation of COVID-19 Therapy
- Conditions
- Interventions
- Drug: Lopinavir-RitonavirBiological: Convalescent plasmaBiological: ImmunoglobulinDrug: CorticosteroidDrug: Synthetic neutralising antibodiesDrug: EmpagliflozinDrug: AnakinraDrug: High Dose CorticosteroidDrug: SotrovimabDrug: PaxlovidDrug: Baloxavir MarboxilDrug: HydroxychloroquineDrug: AzithromycinDrug: TocilizumabDrug: AspirinDrug: Dimethyl fumarateDrug: ColchicineDrug: BaricitinibDrug: OseltamivirDrug: Molnupiravir
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 70000
- Registration Number
- NCT04381936
- Locations
- 🇻🇳
Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
🇬🇭Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana
🇮🇳Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.